This 185-page report provides detailed assessments of such technologies as monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing.  Also included is a review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy.

The report also presents strategic assessments of current and emerging suppliers of cancer diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. 

Contains 185 pages